Glutamate and psychosis risk

Current Pharmaceutical Design

Volumn 18, Issue 4, 2012, Pages 466-478

  Egerton, Alice ^a   Fusar Poli, Paolo ^a   Stone, James M ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Glutamate; Magnetic resonance spectroscopy; Psychosis; Risk; Schizophrenia

Indexed keywords

DOPAMINE; GLUTAMIC ACID;

ADOLESCENT HEALTH; CANNABIS SMOKING; CORPUS STRIATUM; CORTICAL AMYGDALA; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL FACTOR; GENETIC RISK; HEREDITY; HIPPOCAMPUS; HUMAN; MATERNAL DISEASE; MATERNAL STRESS; MENTAL HEALTH; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; STRESS; THALAMUS; TRANSGENIC ANIMAL;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 84856527292     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799316244     Document Type: Review

References (276)

1. Broome MR, Woolley JB, Johns LC, et al. Outreach and support in south london (oasis): Implementation of a clinical service for prodromal psychosis and the at risk mental state. EurPsychiatry 2005; 20(5-6): 372-378.
2. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. SchizophrBull 2007; 33(3): 661-664.
3. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: Validation of personal assessment and crisis evaluation clinic intake criteria. AustNZJPsychiatry 2000; 34 Suppl: S164-S169.
4. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12- month follow up of a high-risk (Prodromal) group. Schizophrenia research 2003; 60(1): 21-32.
5. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: A review and future directions. J of clinical psychiatry 2009; 70(9): 1206-12.
6. Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkotter J. Intervention in at-risk states for developing psychosis. European archives of psychiatry and clinical neuroscience 2010; 260 Suppl 2: S90-S94.
7. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. ArchGenPsychiatry 2009; 66(1): 13-20.
8. Allen P, Chaddock CA, Howes OD, Egerton A, Seal ML, Fusar- Poli P, et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophrenia bulletin 2011.
9. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: A multimodal imaging study. Archives of general psychiatry 2010; 67(7): 683-691.
10. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Molecular psychiatry 2011; 16(1): 67-75.
11. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A pet study. Molecular psychiatry 2011.
12. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. The American journal of psychiatry 2006; 163(5): 790-799.
13. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of general psychiatry 2002; 59(10): 921-928.
14. Ruhrmann S, Bechdolf A, Kuhn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. The British journal of psychiatry Supplement 2007; 51: s88-s95.
15. Yung AR, Phillips LJ, Nelson B, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6- month analysis. J of clinical psychiatry 2011; 72(4): 430-440.
16. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Archives of general psychiatry 2010; 67(2): 146-154.
17. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. The British journal of psychiatry: J of mental science 2004; 185: 291-297.
18. Woods SWW, B.; Pearlson, G.D.; McGlashan, T.H. Glycine treatment of prodromal symptoms. Schizophr Res 2006; 86 (Suppl): S7.
19. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011.
20. Stone JM, Day F, Tsagaraki H, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume. BiolPsychiatry 2009; 66(6): 533-539.
21. Stone JM. Imaging the glutamate system in humans: Relevance to drug discovery for schizophrenia. CurrPharmDes 2009; 15(22): 2594-602.
22. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179(1): 144-150.
23. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of dcycloserine added to conventional neuroleptics in patients with schizophrenia. ArchGenPsychiatry 1999; 56(1): 21-27.
24. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. BiolPsychiatry 2004; 55(2): 165-171.
25. Heresco-Levy U, Javitt DC. Comparative effects of glycine and dcycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis. SchizophrRes 2004; 66(2-3): 89-96.
26. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. BiolPsychiatry 2005; 57(6): 577-585.
27. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. BrJPsychiatry 1996; 169(5): 610-617.
28. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. ArchGenPsychiatry 1999; 56(1): 29-36.
29. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. IntJNeuropsychopharmacol 2001; 4(4): 385-391.
30. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. AmJPsychiatry 1994; 151(8): 1234-1236.
31. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter i inhibitor, n-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. BiolPsychiatry 2004; 55(5): 452-456.
32. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. BiolPsychiatry 1998; 44(11): 1081-1089.
33. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. BiolPsychiatry 2006; 59(3): 230-234.
34. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. AmJPsychiatry 1999; 156(11): 1822-1825.
35. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. The American journal of psychiatry 1991; 148(11): 1474-1486.
36. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version iii--the final common pathway. Schizophrenia bulletin 2009; 35(3): 549-562.
37. Snyder SH. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. The American journal of psychiatry 1976; 133(2): 197-202.
38. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987; 91(4): 415-33.
39. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta pharmacologica et toxicologica 1963; 20: 140-144.
40. Seeman P, Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188(4194): 1217-1219.
41. Gefvert O, Lindstrom LH, Waters N, Waters S, Carlsson A, Tedroff J. Different corticostriatal patterns of l-dopa utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scandinavian journal of psychology 2003; 44(3): 289-292.
42. Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophrenia research 1999; 35(1): 41-50.
43. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346(8983): 1130-1131.
44. Kumakura Y, Cumming P, Vernaleken I, et al. Elevated [18f]fluorodopamine turnover in brain of patients with schizophrenia: An [18f]fluorodopa/positron emission tomography study. J of neuroscience: the official journal of the Society for Neuroscience 2007; 27(30): 8080-8087.
45. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11c) dopa and pet. Biological psychiatry 1999; 46(5): 681-688.
46. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature neuroscience 2002; 5(3): 267-271.
47. Nozaki S, Kato M, Takano H, et al. Regional dopamine synthesis in patients with schizophrenia using l-[beta-11c]dopa pet. Schizophrenia research 2009; 108(1-3): 78-84.
48. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proceedings of the National Academy of Sciences of the United States of America 1994; 91(24): 11651-1164.
49. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009; 65(12): 1091-1093.
50. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. ProcNatlAcadSci USA 1997; 94(6): 2569-2574.
51. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamineinduced dopamine release in drug-free schizophrenic subjects. ProcNatlAcadSciUSA 1996; 93(17): 9235-9240.
52. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of d2 receptors by dopamine in schizophrenia. ProcNatlAcadSciUSA 2000; 97(14): 8104-8109.
53. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67(3): 231-239.
54. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine d2 receptor occupancy. Archives of general psychiatry 2000; 57(6): 553-559.
55. Nordstrom AL, Farde L, Wiesel FA, et al. Central d2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind pet study of schizophrenic patients. Biological psychiatry 1993; 33(4): 227-235.
56. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. The American journal of psychiatry 1989; 146(7): 905-908.
57. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from pet and spect imaging. CurrPharmDes 2009; 15(22): 2550-2559.
58. Haber SN. The primate basal ganglia: Parallel and integrative networks. J Chem Neuroanat 2003; 26(4): 317-330.
59. Stone JM, Bressan RA, Erlandsson K, Ell PJ, Pilowsky LS. Nonuniform blockade of intrastriatal d2/d3 receptors by risperidone and amisulpride. Psychopharmacology 2005; 180(4): 664-669.
60. Bloemen OJ, Gleich T, Koning MB, et al. Hippocampal glutamate levels and striatal dopamine d(2/3) receptor occupancy in subjects at ultra high risk of psychosis. BiolPsychiatry 2011.
61. Javitt DC. Glutamatergic theories of schizophrenia. The Israel journal of psychiatry and related sciences 2010; 47(1): 4-16.
62. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl- JMed 2005; 353(12): 1209-1223.
63. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. AmJPsychiatry 1991; 148(10): 1301-1308.
64. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. Nmda receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169(3-4): 215-233.
65. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. ArchGenPsychiatry 1994; 51(3): 199-214.
66. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6(6): 869-872.
67. Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT, Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. AmJPsychiatry 2001; 158(11): 1797-1808.
68. Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17(3): 141-150.
69. Coyle JT, Tsai G. The nmda receptor glycine modulatory site: A therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004; 174(1): 32-38.
70. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40(5): 881-884.
71. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia-- all roads lead to dopamine. European neuropsychopharmacology: J of the European College of Neuropsychopharmacology 2007; 17 Suppl 2: S101-S107.
72. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia--therapeutic implications. BiolPsychiatry 1999; 46(10): 1388-1395.
73. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and gaba in schizophrenia: New evidence. AnnuRevPharmacolToxicol 2001; 41: 237-260.
74. Laruelle M, Frankle WG, Narendran R, Kegeles LS, bi-Dargham A. Mechanism of action of antipsychotic drugs: From dopamine d(2) receptor antagonism to glutamate nmda facilitation. ClinTher 2005; 27 Suppl A: S16-S24.
75. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. AnnNYAcadSci 2003; 1003: 138-158.
76. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. NatMed 2006; 12(9): 1016-1022.
77. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nature neuroscience 2003; 6(9): 968-973.
78. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007; 30(5): 220-227.
79. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 2006; 31(7): 1356-1361.
80. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. AnnNYAcadSci 2003; 1003: 53-74.
81. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. Modulation of amphetamineinduced striatal dopamine release by ketamine in humans: Implications for schizophrenia. BiolPsychiatry 2000; 48(7): 627-640.
82. Miller DW, Abercrombie ED. Effects of mk-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain ResBull 1996; 40(1): 57-62.
83. Berridge KC, Robinson TE. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28(3): 309-369.
84. Robbins TW, Everitt BJ. Functional studies of the central catecholamines. Int Rev Neurobiol 1982; 23: 303-365.
85. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997; 7(2): 191-197.
86. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1): 13-23.
87. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis- linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79(1): 59-68.
88. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: Burst firing. J of neuroscience: the official journal of the Society for Neuroscience 1984; 4(11): 2877-2890.
89. Sesack SR, Carr DB, Omelchenko N, Pinto A. Anatomical substrates for glutamate-dopamine interactions: Evidence for specificity of connections and extrasynaptic actions. AnnNYAcadSci 2003; 1003: 36-52.
90. Zweifel LS, Parker JG, Lobb CJ, et al. Disruption of nmdardependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proceedings of the National Academy of Sciences of the United States of America 2009; 106(18): 7281-7288.
91. Sharp PE. Complimentary roles for hippocampal versus subicular/ entorhinal place cells in coding place, context, and events. Hippocampus 1999; 9(4): 432-43.
92. Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nature neuroscience 2005; 8(6): 805-12.
93. Sesack SR, Grace AA. Cortico-basal ganglia reward network: Microcircuitry. Neuropsychopharmacology 2010; 35(1): 27-47.
94. Freeman AS, Meltzer LT, Bunney BS. Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci 1985; 36(20): 1983-94.
95. Lisman JE, Grace AA. The hippocampal-vta loop: Controlling the entry of information into long-term memory. Neuron 2005; 46(5): 703-13.
96. Lodge DJ, Grace AA. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America 2006; 103(13): 5167-72.
97. Lodge DJ, Grace AA. Developmental pathology, dopamine, stress and schizophrenia. Int J Dev Neurosci 2011; 29(3): 207-13.
98. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. JNeurosci 2007; 27(42): 11424-30.
99. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31(5): 234-42.
100. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumincontaining interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J of neuroscience: the official journal of the Society for Neuroscience 2009; 29(8): 2344-54.
101. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (mam) model of schizophrenia. The European journal of neuroscience 2006; 23(1): 279-84.
102. Abdul-Monim Z, Neill JC, Reynolds GP. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 2007; 21(2): 198-205.
103. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: Differential modulation by antipsychotic drugs. Neuropsychopharmacology 2003; 28(2): 265-75.
104. Benes FM. Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry 1999; 46(5): 589-99.
105. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997; 24(3): 349-55.
106. Gonzalez-Burgos G, Hashimoto T, Lewis DA. Alterations of cortical gaba neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 2010; 12(4): 335-44.
107. Gonzalez-Burgos G, Lewis DA. Gaba neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008; 34(5): 944-61.
108. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6(4): 312-24.
109. Rotaru DC, Yoshino H, Lewis DA, Ermentrout GB, Gonzalez- Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: Relevance for schizophrenia. J of neuroscience: the official journal of the Society for Neuroscience 2011; 31(1): 142-56.
110. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an nmda receptor deficit in medication-free schizophrenic patients. MolPsychiatry 2006; 11(2): 118-9.
111. Cardno AG, Gottesman, II. Twin studies of schizophrenia: From bow-and-arrow concordances to star wars mx and functional genomics. American journal of medical genetics 2000; 97(1): 12-7.
112. Gottesman, II, Shields J. A polygenic theory of schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1967; 58(1): 199-205.
113. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. MolPsychiatry 2005; 10(1): 40-68.
114. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60(12): 1187-92.
115. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, Just the facts What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008; 102(1-3): 1-18.
116. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull 2008; 34(6): 1066-82.
117. Allen NC, Bagade S, McQueen MB, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: The szgene database. Nat Genet 2008; 40(7): 827-34.
118. Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K. Genetic association studies of glutamate, gaba and related genes in schizophrenia and bipolar disorder: A decade of advance. Neuroscience and biobehavioral reviews 2010; 34(6): 958-77.
119. Tiwari AK, Zai CC, Muller DJ, Kennedy JL. Genetics in schizophrenia: Where are we and what next? Dialogues Clin Neurosci 2010; 12(3): 289-303.
120. Collier DA, Li T. The genetics of schizophrenia: Glutamate not dopamine? European journal of pharmacology 2003; 480(1-3): 177-84.
121. Greenwood TA, Lazzeroni LC, Murray SS, et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the consortium on the genetics of schizophrenia. Am J Psychiatry 2011.
122. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361(9355): 417-9.
123. Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: A pathway analysis of gwas data. Schizophr Res 2010; 122(1-3): 38-42.
124. Harrison PJ, West VA. Six degrees of separation: On the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and nmda receptors. Molecular psychiatry 2006; 11(11): 981-3.
125. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. Journal of neurochemistry 2000; 75(3): 889-907.
126. Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the n-methyl-d-aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America 2000; 97(9): 4926-31.
127. Fadda E, Danysz W, Wroblewski JT, Costa E. Glycine and d-serine increase the affinity of n-methyl-d-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology 1988; 27(11): 1183-5.
128. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates nmda-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003; 89(2): 691-703.
129. Bendikov I, Nadri C, Amar S, et al. A csf and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90(1-3): 41-51.
130. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in neuropsychopharmacology & biological psychiatry 2005; 29(5): 767-9.
131. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of d-serine in patients with schizophrenia: Evidence in support of the n-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60(6): 572-6.
132. Hayashi-Takagi A, Sawa A. Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during neurodevelopment. Brain research bulletin 2010; 83(3-4): 140-6.
133. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbb4 signaling contributes to nmda receptor hypofunction in schizophrenia. Nat Med 2006; 12(7): 824-8.
134. Ikonomidou C, Bosch F, Miksa M, et al. Blockade of nmda receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283(5398): 70-4.
135. Bock J, Braun K. Blockade of n-methyl-d-aspartate receptor activation suppresses learning-induced synaptic elimination. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(5): 2485-90.
136. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric nmda receptors during development of rat cortex. Nature 1994; 368(6467): 144-7.
137. van Zundert B, Yoshii A, Constantine-Paton M. Receptor compartmentalization and trafficking at glutamate synapses: A developmental proposal. Trends Neurosci 2004; 27(7): 428-37.
138. Yashiro K, Philpot BD. Regulation of nmda receptor subunit expression and its implications for ltd, ltp, and metaplasticity. Neuropharmacology 2008; 55(7): 1081-94.
139. Farber NB, Wozniak DF, Price MT, et al. Age-specific neurotoxicity in the rat associated with nmda receptor blockade: Potential relevance to schizophrenia? Biol Psychiatry 1995; 38(12): 788-96.
140. Thompson JL, Pogue-Geile MF, Grace AA. Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms. Schizophr Bull 2004; 30(4): 875-900.
141. Anastasio NC, Xia Y, O'Connor ZR, Johnson KM. Differential role of n-methyl-d-aspartate receptor subunits 2a and 2b in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits. Neuroscience 2009; 163(4): 1181-91.
142. Broberg BV, Dias R, Glenthoj BY, Olsen CK. Evaluation of a neurodevelopmental model of schizophrenia--early postnatal pcp treatment in attentional set-shifting. Behav Brain Res 2008; 190(1): 160-3.
143. du Bois TM, Huang XF. Early brain development disruption from nmda receptor hypofunction: Relevance to schizophrenia. Brain Res Rev 2007; 53(2): 260-70.
144. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia. Neuroscience 2001; 107(4): 535-50.
145. Desbonnet L, Waddington JL, O'Tuathaigh CM. Mutant models for genes associated with schizophrenia. Biochem Soc Trans 2009; 37(Pt 1): 308-12.
146. Ballard TM, Pauly-Evers M, Higgins GA, et al. Severe impairment of nmda receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J of neuroscience: the official journal of the Society for Neuroscience 2002; 22(15): 6713-23.
147. Belforte JE, Zsiros V, Sklar ER, et al. Postnatal nmda receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature neuroscience 2010; 13(1): 76-83.
148. Perrin M, Kleinhaus K, Messinger J, Malaspina D. Critical periods and the developmental origins of disease: An epigenetic perspective of schizophrenia. Ann N Y Acad Sci 2010; 1204 Suppl: E8-13.
149. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468(7321): 203-12.
150. Eells JB, Misler JA, Nikodem VM. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in nurr1-null heterozygous mice. Neuroscience 2006; 140(4): 1117-26.
151. Eisenberg DP, Berman KF. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 2010; 35(1): 258-77.
152. Meyer-Lindenberg A. Imaging genetics of schizophrenia. Dialogues Clin Neurosci 2010; 12(4): 449-56.
153. Tan HY, Callicott JH, Weinberger DR. Prefrontal cognitive systems in schizophrenia: Towards human genetic brain mechanisms. Cogn Neuropsychiatry 2009; 14(4-5): 277-98.
154. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes. Neuroscience and biobehavioral reviews 2010; 34(5): 689-700.
155. Egan MF, Straub RE, Goldberg TE, et al. Variation in grm3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(34): 12604-9.
156. Marenco S, Steele SU, Egan MF, et al. Effect of metabotropic glutamate receptor 3 genotype on n-acetylaspartate measures in the dorsolateral prefrontal cortex. Am J Psychiatry 2006; 163(4): 740-2.
157. Goldberg TE, Straub RE, Callicott JH, et al. The g72/g30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006; 31(9): 2022-32.
158. Prata DP, Papagni SA, Mechelli A, et al. Effect of d-amino acid oxidase activator (daoa; g72) on brain function during verbal fluency. Human brain mapping 2011.
159. Callicott JH, Straub RE, Pezawas L, et al. Variation in disc1 affects hippocampal structure and function and increases risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(24): 8627-32.
160. Prata DP, Mechelli A, Fu CH, et al. Effect of disrupted-inschizophrenia- 1 on pre-frontal cortical function. Molecular psychiatry 2008; 13(10): 915-7, 09.
161. Kircher T, Krug A, Markov V, et al. Genetic variation in the schizophrenia-risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. Human brain mapping 2009; 30(10): 3406-16.
162. Krug A, Markov V, Leube D, et al. Genetic variation in the schizophrenia-risk gene neuregulin1 correlates with personality traits in healthy individuals. Eur Psychiatry 2008; 23(5): 344-9.
163. Mechelli A, Prata DP, Fu CH, et al. The effects of neuregulin1 on brain function in controls and patients with schizophrenia and bipolar disorder. Neuroimage 2008; 42(2): 817-26.
164. Cannon TD, Hennah W, van Erp TG, et al. Association of disc1/trax haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry 2005; 62(11): 1205-13.
165. Dutt A, McDonald C, Dempster E, et al. The effect of comt, bdnf, 5-htt, nrg1 and dtnbp1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol Med 2009; 39(11): 1783-97.
166. Gruber O, Falkai P, Schneider-Axmann T, Schwab SG, Wagner M, Maier W. Neuregulin-1 haplotype hap(ice) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. Journal of psychiatric research 2008; 43(1): 1-6.
167. Konrad A, Vucurevic G, Musso F, Stoeter P, Dahmen N, Winterer G. Erbb4 genotype predicts left frontotemporal structural connectivity in human brain. Neuropsychopharmacology 2009; 34(3): 641-50.
168. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. Additive effect of nrg1 and disc1 genes on lateral ventricle enlargement in first episode schizophrenia. Neuroimage 2010; 53(3): 1016-22.
169. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry 2009; 65(6): 535-40.
170. McIntosh AM, Moorhead TW, Job D, et al. The effects of a neuregulin 1 variant on white matter density and integrity. Molecular psychiatry 2008; 13(11): 1054-9.
171. Szeszko PR, Lipsky R, Mentschel C, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Molecular psychiatry 2005; 10(7): 631-6.
172. Wang F, Jiang T, Sun Z, et al. Neuregulin 1 genetic variation and anterior cingulum integrity in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 2009; 34(3): 181-6.
173. Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with nrg1, erbb4, and akt1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry 2010; 67(10): 991-1001.
174. Tan HY, Chen Q, Sust S, et al. Epistasis between catechol-omethyltransferase and type ii metabotropic glutamate receptor 3 genes on working memory brain function. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(30): 12536-41.
175. Nixon DC, Prust MJ, Sambataro F, et al. Interactive effects of daoa (g72) and catechol-o-methyltransferase on neurophysiology in prefrontal cortex. Biol Psychiatry 2011; 69(10): 1006-8.
176. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93(1): 23-58.
177. Stilo SA, Murray RM. The epidemiology of schizophrenia: Replacing dogma with knowledge. Dialogues Clin Neurosci 2010; 12(3): 305-15.
178. Marcelis M, Takei N, van Os J. Urbanization and risk for schizophrenia: Does the effect operate before or around the time of illness onset? Psychol Med 1999; 29(5): 1197-203.
179. March D, Hatch SL, Morgan C, et al. Psychosis and place. Epidemiol Rev 2008; 30: 84-100.
180. McGrath J, Scott J. Urban birth and risk of schizophrenia: A worrying example of epidemiology where the data are stronger than the hypotheses. Epidemiologia e psichiatria sociale 2006; 15(4): 243-6.
181. Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001; 58(11): 1039-46.
182. Boydell J, van Os J, McKenzie K, et al. Incidence of schizophrenia in ethnic minorities in london: Ecological study into interactions with environment. BMJ 2001; 323(7325): 1336-8.
183. Veling W, Susser E, van Os J, Mackenbach JP, Selten JP, Hoek HW. Ethnic density of neighborhoods and incidence of psychotic disorders among immigrants. Am J Psychiatry 2008; 165(1): 66-73.
184. Cantor-Graae E, Selten JP. Schizophrenia and migration: A metaanalysis and review. Am J Psychiatry 2005; 162(1): 12-24.
185. Selten JP, Cantor-Graae E. Social defeat: Risk factor for schizophrenia? Br J Psychiatry 2005; 187: 101-2.
186. Veling W, Selten JP, Susser E, Laan W, Mackenbach JP, Hoek HW. Discrimination and the incidence of psychotic disorders among ethnic minorities in the netherlands. Int J Epidemiol 2007; 36(4): 761-8.
187. Allardyce J, Gilmour H, Atkinson J, Rapson T, Bishop J, McCreadie RG. Social fragmentation, deprivation and urbanicity: Relation to first-admission rates for psychoses. Br J Psychiatry 2005; 187: 401-6.
188. Kirkbride JB, Morgan C, Fearon P, Dazzan P, Murray RM, Jones PB. Neighbourhood-level effects on psychoses: Re-examining the role of context. Psychol Med 2007; 37(10): 1413-25.
189. Bebbington P, Wilkins S, Jones P, et al. Life events and psychosis. Initial results from the camberwell collaborative psychosis study. Br J Psychiatry 1993; 162: 72-9.
190. Norman RM, Malla AK. Stressful life events and schizophrenia. I: A review of the research. Br J Psychiatry 1993; 162: 161-6.
191. Tessner KD, Mittal V, Walker EF. Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr Bull 2009; 37(2): 432-41.
192. Miczek KA, Yap JJ, Covington HE, 3rd. Social stress, therapeutics and drug abuse: Preclinical models of escalated and depressed intake. Pharmacol Ther 2008; 120(2): 102-28.
193. Covington HE, 3rd, Tropea TF, Rajadhyaksha AM, Kosofsky BE, Miczek KA. Nmda receptors in the rat vta: A critical site for social stress to intensify cocaine taking. Psychopharmacology (Berl) 2008; 197(2): 203-16.
194. Yap JJ, Covington HE, 3rd, Gale MC, Datta R, Miczek KA. Behavioral sensitization due to social defeat stress in mice: Antagonism at mglur5 and nmda receptors. Psychopharmacology (Berl) 2005; 179(1): 230-9.
195. Pistovcakova J, Makatsori A, Sulcova A, Jezova D. Felbamate reduces hormone release and locomotor hypoactivity induced by repeated stress of social defeat in mice. European neuropsychopharmacology: J of the European College of Neuropsychopharmacology 2005; 15(2): 153-8.
196. Herman JP, Cullinan WE, Morano MI, Akil H, Watson SJ. Contribution of the ventral subiculum to inhibitory regulation of the hypothalamo-pituitary-adrenocortical axis. J Neuroendocrinol 1995; 7(6): 475-82.
197. O'Mahony CM, Clarke G, Gibney S, Dinan TG, Cryan JF. Strain differences in the neurochemical response to chronic restraint stress in the rat: Relevance to depression. Pharmacol Biochem Behav 2011; 97(4): 690-9.
198. Valenti O, Lodge DJ, Grace AA. Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J of neuroscience: the official journal of the Society for Neuroscience 2011; 31(11): 4280-9.
199. Pickering C, Gustafsson L, Cebere A, Nylander I, Liljequist S. Repeated maternal separation of male wistar rats alters glutamate receptor expression in the hippocampus but not the prefrontal cortex. Brain research 2006; 1099(1): 101-8.
200. Roceri M, Hendriks W, Racagni G, Ellenbroek BA, Riva MA. Early maternal deprivation reduces the expression of bdnf and nmda receptor subunits in rat hippocampus. Molecular psychiatry 2002; 7(6): 609-16.
201. Bellinger FP, Davidson MS, Bedi KS, Wilce PA. Ethanol prevents nmda receptor reduction by maternal separation in neonatal rat hippocampus. Brain research 2006; 1067(1): 154-7.
202. Krugers HJ, Koolhaas JM, Bohus B, Korf J. A single social stressexperience alters glutamate receptor-binding in rat hippocampal ca3 area. Neuroscience letters 1993; 154(1-2): 73-7.
203. Hui JJ, Zhang ZJ, Liu SS, et al. Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: A magnetic resonance study. Behav Brain Res 2011; 217(1): 122-7.
204. Oreland S, Nylander I, Pickering C. Prolonged maternal separation decreases granule cell number in the dentate gyrus of 3-week-old male rats. Int J Dev Neurosci 2010; 28(2): 139-44.
205. Malaspina D, Corcoran C, Kleinhaus KR, et al. Acute maternal stress in pregnancy and schizophrenia in offspring: A cohort prospective study. BMC Psychiatry 2008; 8: 71.
206. van Os J, Selten JP. Prenatal exposure to maternal stress and subsequent schizophrenia. The may 1940 invasion of the netherlands. Br J Psychiatry 1998; 172: 324-6.
207. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010; 90(3): 285-326.
208. Son GH, Geum D, Chung S, et al. Maternal stress produces learning deficits associated with impairment of nmda receptor-mediated synaptic plasticity. J of neuroscience: the official journal of the Society for Neuroscience 2006; 26(12): 3309-18.
209. Jia N, Yang K, Sun Q, et al. Prenatal stress causes dendritic atrophy of pyramidal neurons in hippocampal ca3 region by glutamate in offspring rats. Dev Neurobiol 2010; 70(2): 114-25.
210. Bradbury TN, Miller GA. Season of birth in schizophrenia: A review of evidence, methodology, and etiology. Psychol Bull 1985; 98(3): 569-94.
211. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia. Schizophr Bull 2003; 29(3): 587-93.
212. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61(8): 774-80.
213. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988; 45(2): 189-92.
214. Brown AS, Cohen P, Harkavy-Friedman J, et al. A.E. Bennett research award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 2001; 49(6): 473-86.
215. Patterson PH. Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 2009; 204(2): 313-21.
216. Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J of neuroscience: the official journal of the Society for Neuroscience 2003; 23(1): 297-302.
217. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008; 22(4): 469-86.
218. Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003; 28(10): 1778-89.
219. Zuckerman L, Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. Journal of psychiatric research 2005; 39(3): 311-23.
220. Morgane PJ, Mokler DJ, Galler JR. Effects of prenatal protein malnutrition on the hippocampal formation. Neuroscience and biobehavioral reviews 2002; 26(4): 471-83.
221. Palmer AA, Brown AS, Keegan D, et al. Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding. Brain research 2008; 1237: 62-74.
222. Palmer AA, Printz DJ, Butler PD, Dulawa SC, Printz MP. Prenatal protein deprivation in rats induces changes in prepulse inhibition and nmda receptor binding. Brain research 2004; 996(2): 193-201.
223. Tonkiss J, Almeida SS, Galler JR. Prenatally malnourished female but not male rats show increased sensitivity to mk-801 in a differential reinforcement of low rates task. Behav Pharmacol 1998; 9(1): 49-60.
224. McGrath J. Hypothesis: Is low prenatal vitamin d a risk-modifying factor for schizophrenia? Schizophr Res 1999; 40(3): 173-7.
225. McGrath JJ, Burne TH, Feron F, Mackay-Sim A, Eyles DW. Developmental vitamin d deficiency and risk of schizophrenia: A 10- year update. Schizophr Bull 2010; 36(6): 1073-8.
226. Kesby JP, Burne TH, McGrath JJ, Eyles DW. Developmental vitamin d deficiency alters mk 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia. Biol Psychiatry 2006; 60(6): 591-6.
227. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin d3 and brain development. Neuroscience 2003; 118(3): 641-53.
228. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of swedish conscripts. Lancet 1987; 2(8574): 1483-6.
229. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325(7374): 1212-3.
230. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33(1): 15-21.
231. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330(7481): 11.
232. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370(9584): 319-28.
233. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002; 156(4): 319-27.
234. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in swedish conscripts of 1969: Historical cohort study. BMJ 2002; 325(7374): 1199.
235. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoidmediated synaptic plasticity in the cns. Annu Rev Neurosci 2006; 29: 37-76.
236. Freund TF, Hajos N. Excitement reduces inhibition via endocannabinoids. Neuron 2003; 38(3): 362-5.
237. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296(5568): 678-82.
238. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR. Opposing actions of chronic delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem 2007; 14(1-2): 63-74.
239. Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, Manzoni OJ. A single in-vivo exposure to delta 9thc blocks endocannabinoid-mediated synaptic plasticity. Nature neuroscience 2004; 7(6): 585-6.
240. Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 2007; 316(5828): 1212-6.
241. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M. The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. European archives of psychiatry and clinical neuroscience 2009; 259(7): 371-82.
242. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during cns development. Trends in pharmacological sciences 2007; 28(2): 83-92.
243. Mulder J, Aguado T, Keimpema E, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(25): 8760-5.
244. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabisinduced schizophrenia. Prog Neurobiol 2010; 92(3): 370-85.
245. Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment. PharmacolTher 2003; 97(2): 153-79.
246. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain ResBrain ResRev 2000; 31(2-3): 288-94.
247. Byun MS, Choi JS, Yoo SY, et al. Depressive symptoms and brain metabolite alterations in subjects at ultra-high risk for psychosis: A preliminary study. Psychiatry Investig 2009; 6(4): 264-71.
248. Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A (1)h spectroscopy study. SchizophrRes 2009; 115(1): 88-93.
249. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. Nmda antagonist neurotoxicity: Mechanism and prevention. Science 1991; 254(5037): 1515-8.
250. Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR. Bilateral blockade of nmda receptors in anterior thalamus by dizocilpine (mk-801) injures pyramidal neurons in rat retrosplenial cortex. EurJNeurosci 2000; 12(4): 1420-30.
251. Stone JM, Bramon E, Pauls A, Sumich A, McGuire PK. Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials. Psychiatry Res 2010; 183(2): 174-6.
252. Klostermann F, Wahl M, Marzinzik F, Schneider GH, Kupsch A, Curio G. Mental chronometry of target detection: Human thalamus leads cortex. Brain 2006; 129(Pt 4): 923-31.
253. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual contextdependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000; 57(12): 1139-47.
254. Bramon E, Shaikh M, Broome M, et al. Abnormal p300 in people with high risk of developing psychosis. Neuroimage 2008; 41(2): 553-60.
255. Bramon E, Croft RJ, McDonald C, Virdi GK, Gruzelier JG, Baldeweg T, et al. Mismatch negativity in schizophrenia: A family study. Schizophr Res 2004; 67(1): 1-10.
256. Fusar-Poli P, Stone JM, Broome MR, et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. ArchGenPsychiatry 2011.
257. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, et al. Proton mrs in twin pairs discordant for schizophrenia. MolPsychiatry 2010; 15(3): 308-18.
258. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P. Elevated 3t proton mrs glutamate levels associated with poor continuous performance test (cpt-0x) scores and genetic risk for schizophrenia. SchizophrRes 2008; 99(1-3): 218-24.
259. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-t proton mrs investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. AmJPsychiatry 2004; 161(6): 1116-8.
260. Wood SJ, Kennedy D, Phillips LJ, et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: A multi-modal magnetic resonance study. Neuroimage 2010; 52(1): 62-8.
261. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. BiolPsychiatry 2010.
262. Valli I, Stone J, Mechelli A, et al. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. BiolPsychiatry 2011; 69(1): 97-9.
263. Day M, Langston R, Morris RG. Glutamate-receptor-mediated encoding and retrieval of paired-associate learning. Nature 2003; 424(6945): 205-9.
264. Allen P, Seal ML, Valli I, et al. Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. SchizophrBull 2009.
265. Stone JM, Raffin M, Morrison P, McGuire PK. Review: The biological basis of antipsychotic response in schizophrenia. J Psychopharmacol 2010; 24(7): 953-64.
266. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid iq in schizophrenia: A meta-analytic review. Am J Psychiatry 2008; 165(5): 579-87.
267. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002; 159(7): 1183-9.
268. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the british 1946 birth cohort. Lancet 1994; 344(8934): 1398-402.
269. Ho BC, Andreasen NC, Nopoulos P, Fuller R, Arndt S, Cadoret RJ. Secondary prevention of schizophrenia: Utility of standardized scholastic tests in early identification. Ann Clin Psychiatry 2005; 17(1): 11-8.
270. Lencz T, Smith CW, McLaughlin D, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006; 59(9): 863-71.
271. Reichenberg A. Cognitive impairment as a risk factor for psychosis. Dialogues Clin Neurosci 2005; 7(1): 31-8.
272. Caspi A, Reichenberg A, Weiser M, et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 2003; 65(2-3): 87-94.
273. Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. Disorganization/ cognitive and negative symptom dimensions in the atrisk mental state predict subsequent transition to psychosis. SchizophrBull 2010.
274. Cornblatt BA. The new york high risk project to the hillside recognition and prevention (rap) program. American journal of medical genetics 2002; 114(8): 956-66.
275. Johnstone EC, Ebmeier KP, Miller P, Owens DG, Lawrie SM. Predicting schizophrenia: Findings from the edinburgh high-risk study. Br J Psychiatry 2005; 186: 18-25.
276. Stone JM, Fusar-Poli P. Abnormal thalamic glutamate and liability to psychosis: State or trait marker? SchizophrRes 2009; 115(1): 94-5.